JP6953305B2 - Ｌ−２−ヒドロキシグルタル酸及びストレス誘発性代謝 - Google Patents

Ｌ−２−ヒドロキシグルタル酸及びストレス誘発性代謝 Download PDF

Info

Publication number
JP6953305B2
JP6953305B2 JP2017502940A JP2017502940A JP6953305B2 JP 6953305 B2 JP6953305 B2 JP 6953305B2 JP 2017502940 A JP2017502940 A JP 2017502940A JP 2017502940 A JP2017502940 A JP 2017502940A JP 6953305 B2 JP6953305 B2 JP 6953305B2
Authority
JP
Japan
Prior art keywords
hypoxia
subject
level
cells
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017502940A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017520774A (ja
JP2017520774A5 (enExample
Inventor
アンドリュー エム． イントルコファー，
アンドリュー エム． イントルコファー，
クレッグ ビー． トンプソン，
クレッグ ビー． トンプソン，
Original Assignee
メモリアル スローン ケタリング キャンサー センター
メモリアル スローン ケタリング キャンサー センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター, メモリアル スローン ケタリング キャンサー センター filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2017520774A publication Critical patent/JP2017520774A/ja
Publication of JP2017520774A5 publication Critical patent/JP2017520774A5/ja
Priority to JP2021159462A priority Critical patent/JP7208323B2/ja
Application granted granted Critical
Publication of JP6953305B2 publication Critical patent/JP6953305B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7038—Hypoxia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
JP2017502940A 2014-03-28 2015-03-27 Ｌ−２−ヒドロキシグルタル酸及びストレス誘発性代謝 Expired - Fee Related JP6953305B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021159462A JP7208323B2 (ja) 2014-03-28 2021-09-29 Ｌ－２－ヒドロキシグルタル酸及びストレス誘発性代謝

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461972091P 2014-03-28 2014-03-28
US61/972,091 2014-03-28
PCT/US2015/023038 WO2015148950A1 (en) 2014-03-28 2015-03-27 L-2-hydroxyglutarate and stress induced metabolism

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021159462A Division JP7208323B2 (ja) 2014-03-28 2021-09-29 Ｌ－２－ヒドロキシグルタル酸及びストレス誘発性代謝

Publications (3)

Publication Number Publication Date
JP2017520774A JP2017520774A (ja) 2017-07-27
JP2017520774A5 JP2017520774A5 (enExample) 2018-05-10
JP6953305B2 true JP6953305B2 (ja) 2021-10-27

Family

ID=54196451

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017502940A Expired - Fee Related JP6953305B2 (ja) 2014-03-28 2015-03-27 Ｌ−２−ヒドロキシグルタル酸及びストレス誘発性代謝
JP2021159462A Active JP7208323B2 (ja) 2014-03-28 2021-09-29 Ｌ－２－ヒドロキシグルタル酸及びストレス誘発性代謝

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021159462A Active JP7208323B2 (ja) 2014-03-28 2021-09-29 Ｌ－２－ヒドロキシグルタル酸及びストレス誘発性代謝

Country Status (6)

Country Link
US (2) US10450596B2 (enExample)
EP (1) EP3122893B1 (enExample)
JP (2) JP6953305B2 (enExample)
AU (1) AU2015237241B2 (enExample)
CA (1) CA2943823C (enExample)
WO (1) WO2015148950A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012340192B2 (en) 2011-11-18 2016-04-07 Memorial Sloan-Kettering Cancer Center 2-hydroxyglutarate as a biomarker for chronic hypoxia
US10450596B2 (en) 2014-03-28 2019-10-22 Memorial Sloan-Kettering Cancer Center L-2-hydroxyglutarate and stress induced metabolism
CA3053356A1 (en) * 2017-02-10 2018-08-16 Health Research, Inc. Targeting mitochondrial complex ii to reduce effects of chronic hypoxia
US10500318B1 (en) * 2018-07-03 2019-12-10 Temple Therapeutics BV Dosing regimens for treating hypoxia-associated tissue damage
JP6977999B2 (ja) * 2018-08-22 2021-12-08 国立大学法人京都大学 胚培養培地、及び胚培養方法
FR3097739B1 (fr) * 2019-06-25 2022-03-04 Lnc Therapeutics Bactéries du microbiote intestinal et composition en contenant pour son utilisation dans la prévention et/ou le traitement de maladies caractérisées par l’excès de 2-hydroxyglutarate
CN112830958B (zh) * 2021-02-05 2022-06-14 山东大学 一种特异性响应于d-2-羟基戊二酸的转录调控因子及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US20060084123A1 (en) 2001-12-13 2006-04-20 Harris Adrian L MN and hypoxia
AU2003302132B2 (en) * 2002-11-21 2008-02-21 Inverness Medical Switzerland Gmbh Bodily fluid markers of tissue hypoxia
US20090186358A1 (en) 2007-12-21 2009-07-23 Wyeth Pathway Analysis of Cell Culture Phenotypes and Uses Thereof
EP2406389B1 (en) 2009-03-13 2019-05-08 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
SE534542C2 (sv) 2009-09-30 2011-09-27 Calmark Sweden Ab Testsystem för bestämning av hypoxiutlöst cellskada
WO2011050211A2 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
WO2011143160A2 (en) 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
US20120202883A1 (en) 2011-01-20 2012-08-09 Duke University Effects of idh1 and idh2 mutations on the cellular metabolome
AU2012340192B2 (en) 2011-11-18 2016-04-07 Memorial Sloan-Kettering Cancer Center 2-hydroxyglutarate as a biomarker for chronic hypoxia
EP2788763A4 (en) * 2011-12-09 2015-10-07 Metabolon Inc BIOMARKERS FOR RENAL CANCER AND METHODS OF USE
US8977473B2 (en) 2012-08-29 2015-03-10 Caterpillar Inc. Pressure control strategy for dual fuel compression ignition engine and machine using same
US10450596B2 (en) 2014-03-28 2019-10-22 Memorial Sloan-Kettering Cancer Center L-2-hydroxyglutarate and stress induced metabolism

Also Published As

Publication number Publication date
EP3122893A1 (en) 2017-02-01
US20170175164A1 (en) 2017-06-22
CA2943823C (en) 2023-10-10
CA2943823A1 (en) 2015-10-01
US20200032315A1 (en) 2020-01-30
WO2015148950A1 (en) 2015-10-01
EP3122893A4 (en) 2017-12-13
JP7208323B2 (ja) 2023-01-18
EP3122893B1 (en) 2021-06-02
JP2017520774A (ja) 2017-07-27
AU2015237241B2 (en) 2021-07-29
JP2022008641A (ja) 2022-01-13
US10450596B2 (en) 2019-10-22
US11788112B2 (en) 2023-10-17
AU2015237241A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
JP7208323B2 (ja) Ｌ－２－ヒドロキシグルタル酸及びストレス誘発性代謝
Chen et al. Itaconate inhibits TET DNA dioxygenases to dampen inflammatory responses
Liu et al. α-Ketoglutarate modulates macrophage polarization through regulation of PPARγ transcription and mTORC1/p70S6K pathway to ameliorate ALI/ARDS
Cloonan et al. Mitochondrial iron chelation ameliorates cigarette smoke–induced bronchitis and emphysema in mice
Lao et al. Glutaryl-CoA dehydrogenase suppresses tumor progression and shapes an anti-tumor microenvironment in hepatocellular carcinoma
JP2012526554A (ja) エピメタボリックシフター、多次元細胞内分子、または環境影響因子を使用する代謝性障害の診断のための方法
Shimizu et al. Organic cation transporter Octn1-mediated uptake of food-derived antioxidant ergothioneine into infiltrating macrophages during intestinal inflammation in mice
Feng et al. 3′ UTR variants of TNS3, PHLDB1, NTN4, and GNG2 genes are associated with IgA nephropathy risk in Chinese Han population
Jiang et al. β-Hydroxybutyric acid upregulated by Suhuang antitussive capsule ameliorates cough variant asthma through GSK3β/AMPK-Nrf2 signal axis
Yang et al. HIF-1α pathway orchestration by LCN2: a key player in hypoxia-mediated colitis exacerbation
Tang et al. RETRACTED ARTICLE: Xihuang pill facilitates glioma cell pyroptosis via the POU4F1/STAT3 axis
Song et al. Lactate Metabolism and Lactylation Modification: New Opportunities and Challenges in Cardiovascular Disease
Jiang et al. NSUN2 knockdown ameliorates hepatic glucose and lipid metabolism disorders in type 2 diabetes mellitus through the inhibition of ACSL6 m5C methylation
Liu et al. LncRNA Nron deficiency protects mice from diet-induced adiposity and hepatic steatosis
Sanchez-Roman et al. Two Cockayne Syndrome patients with a novel splice site mutation–clinical and metabolic analyses
Li et al. ALDH2 attenuates radiation-induced lung injury by inhibiting ROS and epithelial-mesenchymal transition mediated by the TGF-β1/Smad pathway
CN110787296A (zh) 一种用于预防或治疗胰腺癌的药物组合物及检测胰腺癌的试剂盒
Tang et al. Serum proteomic and metabolomic profiling of hepatocellular carcinoma patients co-infected with Clonorchis sinensis
Lu et al. Rheb1 deficiency elicits mitochondrial dysfunction and accelerates podocyte senescence through promoting Atp5f1c acetylation
Huang et al. BBOX1 mediates metabolic reprogramming driven by hypoxia and participates in the malignant progress of high-grade serous ovarian cancer
Luo et al. ZBED3 exacerbates hyperglycemia by promoting hepatic gluconeogenesis through CREB signaling
Jiang et al. Fumarate Hydratase Restrains mtDNA Attenuates LPS-Induced Acute Lung Injury Through cGAS-STING Pathways
Zhang et al. Legumain-deficient macrophages regulate inflammation and lipid metabolism in adipose tissues to protect against diet-induced obesity
Zhang et al. Mechanistic insights into TSH-mediated macrophage mitochondrial dysfunction via TSHR signaling in metabolic disorders
Shen et al. Retracted Article: FAM172A controls endoplasmic reticulum (ER) stress related to NF-κB signaling pathway in hepatocellular carcinoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180326

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210326

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210812

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210830

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210929

R150 Certificate of patent or registration of utility model

Ref document number: 6953305

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees